X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
F901318 (olorofim) is F2G’s leading candidate from the orotomide class and is currently being investigated in a Phase 2b open-label study in patients who have limited treatment options for difficult-to-treat invasive, rare fungal mold infections.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: F901318
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
Olorofim (formerly, F901318) is F2G’s leading candidate from the orotomide class and is currently being investigated in a Phase 2b open-label study in patients who have limited treatment options for difficult-to-treat invasive, rare fungal mold infections.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: Olorofim
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Olorofim (formerly, F901318) is F2G’s leading candidate from the orotomide class for treatment options for difficult-to-treat invasive, rare fungal mold infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and other rare mold infections.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: Olorofim
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
The proceeds from the financing with Shionogi & Co., Ltd., will enable F2G to advance late-stage development and commercialization in the US of F901318 (olorofim), a novel oral antifungal therapy to treat invasive aspergillosis and other rare mold infections.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: F901318
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 04, 2022
Details:
Under the terms of the agreement, Shionogi will conduct the clinical trials of Olorofim, a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis and other rare mold infections, and commercialization of olorofim for IA in Europe and Asia.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: Olorofim
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: $480.0 million Upfront Cash: $100.0 million
Deal Type: Collaboration May 16, 2022
Details:
Olorofim has been well tolerated across more than 30 years of cumulative patient dosing days with a median therapy duration of 12 weeks, in an ongoing open-label single-arm Phase 2b study in patients with proven invasive fungal disease.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: F901318
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Proceeds from the financing will be used to fund F2G's late-stage clinical programs for their novel antifungal agent olorofim and organisational scale-up in preparation for commercialisation.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: F901318
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen Healthcare Investments
Deal Size: $60.8 million Upfront Cash: Undisclosed
Deal Type: Financing August 12, 2020
Details:
Following the granting of Breakthrough Therapy designation in November, the U.S. FDA has also granted Qualified Infectious Disease Product (QIDP) designation to its lead first-in-class candidate, olorofim (formerly F901318).
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
